<DOC>
	<DOCNO>NCT00830219</DOCNO>
	<brief_summary>The purpose study compare relative bioavailability test formulation ropinirole hydrochloride 0.25 mg tablet ( Manufactured distribute TEVA Pharmaceuticals USA ) already approve formulation REQUIP® ( ropinirole hydrochloride ) 0.25 mg tablet ( GlaxoSmithKline ) feed condition healthy , adult subject .</brief_summary>
	<brief_title>The Relative Bioavailability Study Two Ropinirole 0.25 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Males female , 18 45 year age ( inclusive ) , body mass index ( BMI ) 1930 kg/m² inclusive weigh least 120 lb . Sitting ( least 5 minute ) blood pressure least 100/70 sit pulse least 60 b.p.m . Good health determine lack clinically significant abnormality health assessment perform screen . Signed date informed consent form , meet criteria current FDA regulation . If female child bear potential , subject must prepare abstain sexual intercourse use reliable barrier method contraception ( e.g . condom spermicide , IUD ) duration study . Female subject use oral contraceptive within 14 day inject implanted hormonal contraceptive within 180 day dose allowed participate . If female , pregnant , lactating , likely become pregnant study . History allergy sensitivity ropinirole dopamine agonist ( e.g . Corolpam® , Dostinex® , Mirapex® , Permax® , Symmetrel® ) history drug hypersensitivity intolerance , opinion investigator , would compromise safety subject study . History dizziness , lightheadedness faint upon stand . Significant history current evidence chronic infectious disease , system disorder , organ dysfunction , hyper/hypotension , arrhythmia , tachycardia , seizure disorder glaucoma . Presence gastrointestinal disease history malabsorption within last year . History psychiatric disorder occur within last two year require hospitalization medication . Presence medical condition require regular treatment prescription drug . Use pharmacologic agent know significantly induce inhibit drug metabolize enzyme within 30 day prior dose . Receipt drug part research study within 30 day prior dose . Drug alcohol addiction require treatment past 12 month . Donation significant loss whole blood ( 480 ml ) within 30 day plasma within 14 day prior dose . Positive test result HIC , Hepatitis B surface antigen Hepatitis C antibody . Positive test result drug abuse screen . Positive serum pregnancy test . Tobacco user within 90 day first study dose . Unable , unwilling tolerate multiple venipuncture . Difficulty fast eat standard meal provide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>